Hospital

The pharmacy director of Baptist Health South Florida details the features and successes of medication delivery services they provide.

Investigators found high incidences of non-susceptibility with penicillin and increasing resistance to macrolides for pneumococcal diseases.

Ibrutinib and other Bruton tyrosine kinase inhibitors can cause the development of or worsen pre-existing hypertension.

Providing continuity of care with the involvement of midwives also appeared to reduce inequities in care for multi-ethnic patients.

Corticosteroids can reduce the need for mechanical ventilation, incidence of shock, and length of hospital stay, especially for younger patients with community-acquired pneumonia.

The study authors noted that further research with larger populations should be conducted to boost the reliability and generalizability of the results.

A survey that analyzed treatment options and research for patients with NSCLC was conducted with medical oncologists.

Investigators also found that the mortality rates for cardiovascular disease from 2020 to 2022 reversed the improvements of reduced mortalities in the preceding decades.

The investigators identified 4 prognostic factors with high predictive ability and supported by moderate to high strength evidence beyond what is already available for cardiovascular disease.

The 23-valent pneumococcal polysaccharide vaccine was most likely associated with a higher risk of immunological events for those who were immunocompromised, but the events were low.

The investigators found that perceived racism in everyday life was not associated with a higher risk of coronary heart disease—only racism in the 3 specific categories.

The model was designed to help improve health outcomes, improve access to care, and lower costs for gene therapy.

Early signs of psychosis may be used to predict the risk of developing a full psychosis spectrum disorder.

This breathing pattern is called resonant breathing and has been shown to improve heart rate variability.

Leg compression therapy was associated with decreased brain natriuretic peptide levels without any adverse events for patients with stable chronic heart failure.

In a study, more than 28% of participants met an ideal cardiovascular health score at the beginning of the study, with only 16% having ideal cardiovascular health at the 20-year mark.

The company seeks the approval for both the intravenous and subcutaneous administration routes.

Investigators from the University of Liverpool tested the effect of meropenem, an antibiotic used for hospital-acquired pneumonia, to determine how resistance emerges.

Approximately 41% of enrolled patients responded to NX-2127, and the BTK degrader overcame resistance to nearly all BTK mutations that were identified to cause resistance.

According to the authors, the test has promise in guiding treatment but needs further refining to obtain information beyond molecular subtyping.

This approach may help prevent premature deaths attributed to preventable or treatable cardiovascular disease.

These heat-not-burn cigarettes are incorrectly assumed to be healthier than traditional tobacco cigarettes.

The diabetes/weight loss drug has surged in popularity, and new trials are evaluating it for certain pediatric patients.

There are 2 features of weight loss interventions which are most likely to improve weight loss outcomes—having access to professional health coaches and social support from other users.

The company will discontinue the development and commercialization of aducanumab-avwa (Aduhelm) for intravenous use and will terminate the ENVISION clinical study.

In December 2023, the FDA granted expanded indications for bempedoic acid and bempedoic acid plus ezetimibe in the treatment of primary hyperlipidemia.

The diabetes/weight loss drug is be evaluated in trials for pediatric patients who are at least 10 years of age.

Survival rates were similar between non-Hispanic African American and non-Hispanic White patients who received treatment, indicating a need to address barriers to multiple myeloma treatment and racial disparities.

Daratumumab and hyaluronidase-fihj in combination with other therapies was previously approved by the FDA in May 2020 for 8 indications in multiple myeloma.

However, different recommendations may actually be valuable, as different countries have different population-based needs.